Last updated: April 24, 2024
Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Overall Status: Active - Recruiting
Phase
4
Condition
Sleep Apnea Syndromes
Treatment
Melatonin 3 MG Oral Tablet
Clinical Study ID
NCT06380491
REF.2338
UNAM-PAPIIT 32-IN216919
Ages 18-60 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Polisomnographic diagnosis of Obstructive Sleep Apnea
- Non-dipping blood pressure on Ambulatory blood pressure monitoring (ABPM):
Exclusion
Exclusion Criteria:
- Use of sleep or psychiatric medication
- Use of Positive Airway Pressure (CPAP or Bipap)
- Neurologic or psychiatric disorder
Study Design
Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Melatonin 3 MG Oral Tablet
Phase: 4
Study Start date:
June 22, 2023
Estimated Completion Date:
January 22, 2025
Study Description
Connect with a study center
National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ)
Mexico City,
MexicoActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.